Obesity And Diabetes Drugs Demand Help Distributor Cencora Propel Revenue In Q3
Portfolio Pulse from Vandana Singh
Cencora Inc's Q4 FY23 adjusted EPS reached $2.86, beating the consensus of $2.80. Revenue was $68.9 billion, up 12.7% Y/Y, beating the consensus of $66.02 billion, primarily due to increased sales of products for diabetes and weight loss. However, the company's shares are down 2.73% at $192.35.
November 02, 2023 | 7:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cencora's Q4 FY23 results beat consensus estimates, with increased sales of diabetes and weight loss products driving revenue growth. However, the company's shares are down 2.73%.
Despite beating consensus estimates for Q4 FY23, Cencora's shares are down, likely due to market factors. The increased sales of diabetes and weight loss products have driven revenue growth, but the decrease in gross profit margin due to these products, which have lower margins, and lower sales of higher-margin COVID-19 treatments may have impacted investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100